Small molecules dominate the clinical pipeline for Huntington’s disease: Data Byte

After a pair of setbacks in March for the leading antisense oligonucleotides in Huntington’s disease, the clinical pipeline for the indication is dominated by small molecules, but next-generation antisense therapies and a range of other modalities with disease-modifying potential fill the preclinical pipeline.

Last month, Wave Life Sciences Ltd. (NASDAQ:WVE) discontinued two antisense oligonucleotides in Phase Ib/IIa testing, and though still in the pipeline, Ionis Pharmaceuticals Inc. (NASDAQ:IONS) stopped a Phase III trial...